US Earnings Financial Results SEC Filings — September 08, 2026

08-09-2026

enGene Holdings Inc. reported a net loss of $92.5M for the nine months ended July 31, 2026, widening from $79.4M in the same period last year, driven by higher operating expenses. The company raised significant capital through a public offering ($126.3M gross) and a Second Amended Term Loan ($25M), boosting total shareholders' equity to $230.3M from $167.7M at fiscal year-end. However, research and development spending increased only modestly while general and administrative costs surged 56%, contributing to an elevated cash burn with net cash used in operations of $78.3M.

• · Share-based compensation expense for the nine months was $14.8M, more than double the $7.0M in the prior-year period.
• · Prepaid and other current assets increased to $10.5M from $6.6M at fiscal year-end.
• · Accounts payable decreased sharply from $6.7M to $2.5M.
• · A loss on extinguishment of debt of $0.5M was recognized in the nine-month period.
• · Accumulated deficit grew to $464.5M from $372.0M, a 24.9% increase.
• · Net cash used in investing activities was $72.5M, primarily for purchases of marketable securities.

08-09-2026

Barnes & Noble Education, Inc. (BNED) reported a net loss of $12.9M for the 13 weeks ended August 1, 2026, an improvement from the $18.3M net loss in the prior-year period. Total sales increased slightly by 0.8% to $290.6M, driven by modest growth in product sales and general merchandise, while rental income declined. Operating loss narrowed to $17.3M from $23.2M, and the company reduced interest expense and selling and administrative costs. However, cash and cash equivalents decreased to $7.8M from $8.4M at the start of the period, and long-term borrowings rose sharply to $123.5M from $71.0M, indicating increased leverage.

• · Service and Other Revenue declined 5.1% YoY to $20.4M from $21.5M.
• · Course Materials Product Sales grew 1.3% YoY to $180.4M.
• · General Merchandise Product Sales grew 2.1% YoY to $76.0M.
• · Dividends paid of $2.8M during the quarter, compared to none in the prior-year period.
• · Deferred revenue decreased to $12.8M from $13.2M at the start of the period.
• · Stock-based compensation expense fell 57.3% YoY to $1.1M from $2.5M.
• · Total assets increased 14.4% to $846.7M from $739.9M at May 2, 2026, driven largely by higher receivables and inventories.

08-09-2026

Samsara Inc. reported a strong financial performance for the three and six months ended August 1, 2026, achieving net income of $16.2M for Q2 and $60.8M for H1, compared to net losses of $16.8M and $38.9M in the prior-year periods. Revenue grew 29.9% YoY to $508.4M in Q2 and 30.2% to $987.3M in H1, driven by continued adoption of its IoT platform. However, the company experienced a decline in unrealized gains on investments and foreign currency translation adjustments, leading to other comprehensive losses of $2.2M in Q2 and $5.2M in H1, and cash and cash equivalents decreased to $291.4M from $318.8M at the start of the fiscal year.

• · Total stockholders' equity increased to $1.60B as of August 1, 2026 from $1.42B at January 31, 2026.
• · Accumulated deficit improved to -$1.56B from -$1.62B over the same period.
• · Stock-based compensation expense was $173.9M for H1 FY27, up from $158.2M in H1 FY26.
• · Net cash provided by operating activities rose 50.7% YoY to $154.9M in H1 FY27.
• · Cash used in investing activities increased to $129.5M in H1 FY27 from $86.4M in H1 FY26, driven by higher investment purchases.
• · Financing activities used $53.4M in H1 FY27, compared to providing $18.0M in H1 FY26, primarily due to $70.4M in taxes paid for net share settlement of equity awards.
• · Deferred revenue (current) grew to $728.9M from $679.3M, indicating strong subscription growth.
• · Accounts receivable increased to $337.8M from $321.4M, reflecting higher sales.
• · Inventories rose to $57.0M from $48.2M.
• · Connected device costs (current and non-current) totaled $489.5M, up from $440.1M at year-end.
• · Other comprehensive loss was $5.2M for H1 FY27, compared to a gain of $3.1M in H1 FY26, driven by unrealized losses on investments.
• · The company had no preferred stock issued or outstanding.
• · Basic and diluted net income per share was $0.03 for Q2 FY27 and $0.10 for H1 FY27, versus losses of $0.03 and $0.07 in the prior-year periods.

08-09-2026

MMEX Resources Corp filed its 10-Q for the quarter ended July 31, 2026, reporting no revenue and a net loss of $854,294, widening from a $436,139 loss in the prior-year quarter. Cash increased sharply to $1,655,003 from $212,343 at April 30, 2026, primarily due to $3,800,000 in proceeds from the sale of non-controlling interests. However, the company remains deeply unprofitable with an accumulated deficit of $85,921,379 and negative working capital of $3,389,671, while operating cash flow worsened to a use of $1,548,280 from just $8,900 a year ago.

• · Revenue remained zero for both Q2 FY26 and Q2 FY25.
• · General and administrative expenses surged to $939,690 from $298,940, a 214% increase.
• · The company recorded a gain on extinguishment of liabilities of $161,937 in Q2 FY26, compared to none in the prior year.
• · Total liabilities decreased to $6,995,277 from $7,880,717, a reduction of 11.2%.
• · Stockholders' deficit improved to $3,662,057 from $6,607,763, primarily due to the sale of non-controlling interests.
• · The company had $1,154,453 in notes payable currently in default at July 31, 2026.
• · Convertible notes payable – related parties increased to $179,570 from $0 at April 30, 2026.
• · Weighted average shares outstanding nearly doubled to 22,295,726,723 from 11,475,488,377.
• · The company issued convertible promissory notes with make-whole provisions of 18% of principal, resulting in losses on extinguishment of debt.
• · A line of credit of up to $1,000,000 was established on November 5, 2025, with an 18% interest rate and conversion price of $0.000068 per share.

08-09-2026

MiniMed Group, Inc. reported net sales of $843M for the three months ended July 31, 2026, up 16.6% from $723M in the prior-year period, and achieved breakeven net income attributable to the Company compared to a net loss of $19M in the prior year. However, the company generated negative operating cash flow of $49M (improved from -$141M) and reported a comprehensive loss of $2M due to a foreign exchange translation adjustment. Cash and cash equivalents declined sharply from $298M to $207M.

• · Goodwill remained nearly flat at $2.255B (July 31, 2026) vs $2.256B (April 24, 2026).
• · Due from Medtronic increased 32.3% to $602M from $455M, while Due to Medtronic rose 29.9% to $178M from $137M.
• · Accrued compensation decreased 22.7% to $126M from $163M.
• · Accounts payable surged 54.0% to $251M from $163M.
• · Other operating expense (income), net swung to an expense of $36M from income of $2M in the prior year.
• · Certain litigation charges, net were a credit of $2M in Q2 FY26 vs a charge of $17M in Q2 FY25.
• · The company had no net transfers from Parent in Q2 FY26, compared to $202M in Q2 FY25.
• · Capitalized costs in accounts payable and accrued liabilities increased to $42M from $25M.
• · Accumulated other comprehensive loss worsened to -$14M from -$12M due to a translation adjustment of -$2M.
• · The company's effective tax rate was 100% (income tax provision of $4M on pre-tax income of $4M) in Q2 FY26, compared to a negative effective rate in the prior year.

08-09-2026

Mission Produce reported a net loss of $6.5M for Q3 FY2026 vs net income of $14.7M in the prior-year quarter, driven by $12.6M in transaction and integration costs related to the acquisition of Calavo Growers. Revenue grew 25.8% YoY to $450.0M, but gross profit declined slightly to $44.7M from $45.1M. For the nine-month period, net loss attributable to Mission Produce was $14.4M vs net income of $21.7M a year ago, while operating cash flow turned negative at -$25.9M vs positive $21.4M. The company completed the acquisition of Calavo Growers for $466.0M in consideration, funded through a mix of stock issuance (17.5M shares) and new debt, significantly increasing total assets to $1.61B from $983.0M.

• · Transaction advisory and integration costs were $12.6M in Q3 FY2026 and $26.0M for the nine-month period, compared to $0.1M and $0.3M in the prior-year periods.
• · Operating income fell sharply to $0.5M in Q3 FY2026 from $21.0M a year ago; for the nine-month period, operating loss was $4.0M vs income of $37.2M.
• · Interest expense increased to $5.1M in Q3 FY2026 from $2.4M a year ago, reflecting higher debt levels.
• · Goodwill jumped to $268.3M from $39.4M, and intangible assets of $100.7M were recognized (none previously), both due to the Calavo acquisition.
• · The company issued 17,530,762 shares of common stock for the Calavo acquisition, increasing additional paid-in capital by $197.2M.
• · Share repurchases totaled $9.4M in the nine months FY2026 vs $5.5M a year ago, including $7.2M in Q3 alone.
• · Net cash used in operating activities was $25.9M for nine months FY2026 vs $21.4M provided a year ago, driven by working capital outflows.
• · Total debt (short-term borrowings + current portion of long-term debt + long-term debt net) increased to $400.4M from $100.3M at October 31, 2025.
• · The Calavo acquisition contributed identifiable net assets of $239.2M and goodwill of $228.9M.

08-09-2026

Casey's General Stores reported strong Q1 FY27 results for the three months ended July 31, 2026, with total revenue increasing 24.3% YoY to $5.68B and net income rising 27.1% to $273.7M. Diluted EPS grew to $7.37 from $5.77. However, cash flow from operations grew only 3.1% to $384.1M, and the company's cash position remained nearly flat sequentially at $524.1M, while capital expenditures nearly doubled to $194.4M and acquisition spending surged to $43.9M from $9.5M.

• · Dividends declared increased to $0.65 per share in Q1 FY27 from $0.57 per share in Q1 FY26.
• · The company repurchased 54,647 shares in Q1 FY27, compared to 69,687 shares in Q1 FY26.
• · Total liabilities increased to $5.03B at July 31, 2026 from $4.98B at April 30, 2026.
• · Goodwill increased to $1.28B from $1.27B sequentially, partly due to acquisitions.
• · Operating expenses rose 8.0% YoY to $754.1M, while depreciation and amortization increased 6.5% to $116.0M.
• · Interest expense net decreased to $22.1M from $26.9M YoY.
• · The effective tax rate was approximately 21.1% in Q1 FY27 vs 22.7% in Q1 FY26.

08-09-2026

IX Acquisition Corp. reported a net income of $919,774 for Q2 2026, a significant turnaround from a net loss of $516,153 in Q2 2025. For the six-month period, net income was $2,881,657 versus a net loss of $274,028 in the prior year. The improvement was driven by a $2,424,500 gain from the change in fair value of derivative warrant liabilities. However, cash decreased to $104,349 from $178,975 at year-end 2025, and the company continues to operate with a shareholders' deficit of $12,911,224.

• · Cash held in Trust Account increased to $9,066,245 from $8,781,221 at year-end 2025.
• · Derivative warrant liabilities fell sharply to $373,000 from $2,797,500, contributing a $2,424,500 non-cash gain.
• · Promissory note - related party decreased slightly to $3,805,175 from $3,955,175.
• · Deferred underwriting fee payable remained unchanged at $6,050,000.
• · Net cash provided by operating activities was $243,624 for H1 2026, down from $289,621 in H1 2025.
• · Cash used in investing activities was $168,250 for H1 2026, down from $289,867 in H1 2025.
• · The company had no revenue-generating operations, with operating and formation expenses negative (income) of $304,970 for Q2 2026.

08-09-2026

North European Oil Royalty Trust (NRT) reported its quarterly and nine-month results for the period ended July 31, 2026. For the nine months, total royalty income surged 29.4% to $7.24M and net income rose 29.3% to $6.47M, driven by higher gas sales and favorable exchange rates. However, the third fiscal quarter showed only marginal growth: royalty income increased just 0.9% to $2.64M and net income edged up 0.6% to $2.47M, while the distribution per unit actually declined 3.7% to $0.26 from $0.27 a year ago. Cash and cash equivalents decreased 8.8% to $4.36M from $4.79M at the prior year-end, reflecting higher distributions paid.

• · Interest income declined 39.9% in Q3 (from $25,220 to $15,164) and 15.9% year-to-date (from $58,180 to $48,954).
• · Operating expenses increased 26.8% for the nine months (from $640,011 to $811,838).
• · Related party expenses dropped to $0 in Q3 2026 from $3,166 in Q3 2025, and fell 48.7% year-to-date (from $6,817 to $3,495).
• · Distributions paid during the nine months more than doubled, from $2.39M to $6.89M, contributing to the cash decrease.
• · The OEG agreement gas sales volume declined 5.9% in the quarter, while Mobil agreement volume increased 1.6%.
• · Average gas prices under both agreements fell 1.8% in the quarter.
• · The average USD/CAD exchange rate strengthened 0.7% in the quarter.
• · Net income per unit remained flat at $0.27 in Q3, but rose 29.6% year-to-date to $0.70.
• · Distributions per unit for the nine months increased 40.8% to $0.70, matching net income per unit.

08-09-2026

Apnimed reported a net income of $125.9M in Q2 2026 vs a loss of $69.5M in Q2 2025, driven primarily by a $85.4M gain on sale of an equity method investment and a $57.1M gain on reversal of a deposit liability. However, revenue from a related party declined 29% YoY to $12.1M (from $17.1M) in Q2 2026, and operating expenses rose, producing an operating loss of $11.7M (widened from $5.9M loss a year earlier). Cash and cash equivalents surged to $172.8M from $41.9M at year-end 2025, but the company continues to rely on non-core gains to report profitability.

• · The company recorded a $57.1M gain on reversal of deposit liability in Q2 2026, contributing significantly to net income.
• · Deferred revenue dropped from $113.1M at Dec 31, 2025 ($97.8M short-term + $15.2M long-term) to $19.5M (all short-term) at June 30, 2026.
• · Convertible preferred stock liquidation preference increased to $249.5M from $224.5M at year end.
• · Total liabilities decreased to $125.7M from $224.5M at Dec 31, 2025, mainly due to the elimination of deposit liability and reduced deferred revenue.
• · The company had zero deferred revenue long-term as of June 30, 2026 ($15.2M at Dec 31, 2025).
• · Operating lease right-of-use asset decreased to $714k from $835k.
• · Deferred transaction costs of $4.8M were recorded as of June 30, 2026, related to an IPO (net IPO costs paid of $1.8M during H1 2026).

08-09-2026

G-III Apparel Group reported mixed results for the six months ended July 31, 2026. Net sales declined 8.9% YoY to $1.09B, but net income surged 364% to $86.7M, driven by a sharp improvement in gross margin (54.9% vs 41.5%) and a 288% increase in operating profit to $96.1M. However, Q2 net sales fell 9.6% to $554.1M, and operating profit dropped 33.6% to $10.8M, highlighting ongoing top-line pressure.

• · Gross profit for six months ended July 31, 2026 was $598.1M vs $497.0M in prior year, a 20.3% increase despite lower sales.
• · Selling, general and administrative expenses rose 6.2% to $486.7M for the six-month period.
• · Interest and financing charges swung from a net benefit of $0.2M to a net expense of $7.1M for the six-month period.
• · The company repurchased 237,000 shares of common stock for $7.9M during the six months ended July 31, 2026.
• · Cash dividends of $0.10 per share were declared, totaling $8.5M for the six-month period.
• · Accounts receivable net decreased 15.1% YoY to $403.4M, while inventories decreased 13.2% to $555.0M.
• · Total assets increased 2.3% to $2.75B, while total liabilities decreased 5.1% to $932.7M.
• · Operating cash flow improved 5.8% to $178.7M for the six-month period.

08-09-2026

UiPath reported a strong turnaround in Q2 FY27, with total revenue growing 13.4% YoY to $410.3M and net income surging to $36.1M from $1.6M a year ago, driven by operating leverage and a swing to operating income of $31.6M. However, the company continued to burn cash, with cash and equivalents declining 30% from January 2026 to $607.4M, and deferred revenue fell 10% to $543.6M, signaling potential headwinds in future revenue recognition. The balance sheet also weakened as total assets fell 8.6% to $2.91B, partly due to $149.4M in acquisition-related cash outflows and $268.5M in share repurchases.

• · Professional services and other revenue surged 81.6% YoY to $20.3M, but cost of professional services grew even faster at 58.1% YoY, keeping gross margin on that segment thin.
• · Adjusted gross margin (non-GAAP) improved to 81.9% in Q2 FY27 from 84.2% in Q2 FY26, a decline of 230 bps.
• · Operating cash flow was nearly flat at $162.6M for the six months vs $160.6M a year ago, despite the swing to profitability.
• · Goodwill and intangible assets increased sharply to $280.9M from $145.3M at year-end, reflecting acquisition activity.
• · The company repurchased $268.5M of its own stock in the first half of FY27, compared to $329.1M in the prior-year period.
• · Deferred revenue (current + non-current) fell to $615.3M from $707.3M at January 31, 2026, a decline of 13.0%.
• · Net cash used in investing activities was $128.6M, up from $80.6M a year ago, driven by $149.4M in acquisition payments.
• · The effective tax rate spiked to 37.5% for the six months from a negative rate in the prior year, due to a $27.9M deferred tax provision.

08-09-2026

EVI Industries, Inc. filed its 10-K annual report for the fiscal year ended June 30, 2026. The company reported a slight decrease in cash from operations to $20.6M from $21.3M in the prior year, while significantly reducing cash used in investing activities to $14.3M from $51.8M. Selling, general and administrative expenses increased as a percentage of revenue to 28.0% from 26.8%, while cost of sales improved to 68.5% from 69.6%.

• · Goodwill increased to $93.9M at June 30, 2026 from $91.7M at June 30, 2025.
• · Intangible assets, net decreased to $28.9M from $30.9M.
• · Contract assets increased to $632K from $289K.
• · Equipment and improvements, net increased to $20.1M from $17.8M.
• · The company's independent registered public accounting firm is BDO USA, P.C. (PCAOB ID #243).

08-09-2026

ABM Industries reported revenue growth of 4.2% YoY to $2,317.1M for Q3 FY26 and 6.2% YoY to $6,850.6M for the nine-month period. Net income rose 18.9% YoY to $49.7M in Q3, while operating profit increased 9.7% to $91.5M. However, the company incurred $7.8M in restructuring expenses in Q3 (none in prior year), and interest expense grew 16.6% to $29.5M. Cash flow from operations improved sharply to $275.0M from $101.0M, but investing activities used $315.8M, largely due to $242.1M in business acquisitions. The company also repurchased $94.7M of common stock during the nine months, up from $48.5M a year ago.

• · Goodwill increased to $2,741.2M from $2,591.1M, reflecting acquisition activity.
• · Long-term debt, net rose to $1,732.2M from $1,537.1M.
• · Deferred revenue more than doubled to $153.4M from $74.7M.
• · Cash used in investing activities was $315.8M, primarily for business acquisitions of $242.1M.
• · The company repurchased 2.1 million shares in the nine months (vs 1.0 million a year ago).
• · Dividends paid increased to $51.2M from $49.4M.
• · Income tax provision decreased to $13.5M from $17.6M in Q3.
• · Amortization of intangible assets rose to $15.5M from $13.4M in Q3.

08-09-2026

ARC Group Securities Acquisition I filed its 10-Q for the quarter ended June 30, 2026, reporting total assets of $293,513, up from $152,926 at year-end 2025, driven by a $25,000 cash balance and increased deferred offering costs. The company posted a net loss of $45,931 for the three months and $51,529 for the six months ended June 30, 2026, with no revenue generated. Shareholder's deficit deepened to ($113,233) from ($86,704) at December 31, 2025, reflecting ongoing operating losses and reliance on related-party financing.

• · The company had no revenue for the period; all activity relates to formation and operating costs.
• · Deferred offering costs increased to $268,513 from $152,926 at year-end 2025.
• · Accrued offering costs rose to $90,607 from $48,190.
• · Accrued expenses increased to $32,278 from $17,045.
• · Net cash used in operating activities was $36,296 for the six months.
• · Net cash provided by financing activities was $61,296.
• · The company had no cash at the beginning of the period.
• · On May 6, 2026, the Sponsor surrendered 2,217,857 Class B ordinary shares for no consideration, reducing outstanding shares to 5,175,000.
• · An aggregate of 675,000 Class B ordinary shares are subject to forfeiture if the underwriters' over-allotment is not exercised.
• · Subscription receivable was eliminated during the period, with $25,000 received from the Sponsor for ordinary shares.

08-09-2026

VanEck Merk Gold ETF (OUNZ) filed its 10-Q for the quarter ended July 31, 2026, reporting net assets of $2.54B, down from $2.90B at January 31, 2026, driven by a significant unrealized depreciation on gold bullion of $508.1M for the six-month period. The ETF saw net creations of 35,583 ounces of gold contributed versus 9,272 ounces distributed, increasing total ounces held to 626,383. However, the net asset value per share fell from $46.56 to $38.94, reflecting the decline in gold prices, and the fund reported a net investment loss of $3.48M for the six months, up from $1.97M in the prior year period.

• · The fund's net investment loss for the three months ended July31,2026 was $1.68M, compared to $1.08M in the prior year period.
• · Net change in unrealized depreciation on gold bullion for the six months was -$508.08M, versus a gain of $231.08M in the prior year period.
• · Total shares issued and outstanding increased from 62,358,853 at January31,2026 to 65,174,928 at July31,2026.
• · The fund's cost of gold bullion investments increased from $1.38B to $1.53B over the six months.

08-09-2026

Dell Technologies reported strong Q2 FY2027 results with total net revenue of $46,971M, up 57.7% YoY, driven by a 71.8% surge in product revenue to $41,112M, while services revenue was flat at $5,859M (+0.3%). Net income more than tripled to $4,133M from $1,164M, and diluted EPS rose to $6.34 from $1.70. However, the company's balance sheet shows a significant increase in inventories to $21,290M (up 104% from $10,437M) and a negative shareholders' equity of $(1,427)M, reflecting heavy treasury stock repurchases.

• · Gross margin for Q2 FY2027 was $9,830M, up from $5,447M in Q2 FY2026.
• · Operating income for Q2 FY2027 was $5,385M, up from $1,773M in Q2 FY2026.
• · Cash flow from operations for H1 FY2027 was $6,306M, up from $5,339M in H1 FY2026.
• · Capital expenditures and capitalized software development costs for H1 FY2027 were $2,202M, up from $1,243M in H1 FY2026.
• · Treasury stock repurchases for H1 FY2027 totaled $5,477M, up from $2,920M in H1 FY2026.
• · Dividends declared were $0.630 per common share for Q2 FY2027 and $1.260 per common share for H1 FY2027.
• · Total shareholders' deficit improved to $(1,427)M as of July 31, 2026 from $(2,470)M as of January 30, 2026.
• · Accounts receivable increased to $22,918M as of July 31, 2026 from $17,585M as of January 30, 2026.
• · Financing receivables (short-term and long-term) increased to $20,430M as of July 31, 2026 from $14,280M as of January 30, 2026.
• · Long-term debt increased to $25,985M as of July 31, 2026 from $23,513M as of January 30, 2026.

08-09-2026

ServiceTitan reported total revenue of $292.8M for Q2 FY26 (three months ended July 31, 2026), up 20.9% YoY from $242.1M, driven by platform revenue growth of 22.2% to $284.5M. Net loss narrowed 22.7% YoY to $24.9M from $32.2M, and operating loss improved to $27.6M from $34.8M. However, professional services and other revenue declined 12.1% YoY to $8.3M, and the company's accumulated deficit widened to $1.31B from $1.27B at year-start.

• · Gross profit for Q2 FY26 was $209.1M, up 22.0% from $171.3M in Q2 FY25.
• · Total operating expenses for Q2 FY26 were $236.6M, up 14.8% from $206.1M in Q2 FY25.
• · Research and development expenses increased 37.7% YoY to $100.6M in Q2 FY26 from $73.1M.
• · Sales and marketing expenses grew 10.7% YoY to $77.0M in Q2 FY26.
• · General and administrative expenses decreased 7.1% YoY to $59.0M in Q2 FY26.
• · Interest income fell 18.0% YoY to $3.9M in Q2 FY26 from $4.8M.
• · Stock-based compensation expense was $62.4M in Q2 FY26 vs $50.5M in Q2 FY25, a 23.6% increase.
• · Net loss per share (basic and diluted) improved to $(0.26) in Q2 FY26 from $(0.35) in Q2 FY25.
• · Total assets increased 3.4% to $1.80B as of July 31, 2026 from $1.75B at January 31, 2026.
• · Total liabilities decreased 9.7% to $198.5M from $219.8M over the same period.
• · Intangible assets, net decreased 11.1% to $157.0M from $176.7M since January 31, 2026.
• · Accounts receivable increased 24.8% to $69.9M from $56.0M since January 31, 2026.
• · Accrued personnel-related expenses dropped 37.1% to $52.3M from $83.1M since January 31, 2026.
• · Deferred revenue decreased 6.8% to $17.4M from $18.7M since January 31, 2026.
• · Net cash provided by operating activities more than doubled to $56.4M in H1 FY26 from $25.8M in H1 FY25.
• · Capitalized internal-use software spending was $11.4M in H1 FY26, nearly flat vs $11.4M in H1 FY25.

08-09-2026

Braveheart Bio, Inc. filed its 10-Q for the period ended June 30, 2026, reporting a net loss of $14,988K for Q2 2026 and $29,268K for the first half of 2026, compared to losses of $381K and $480K in the prior-year periods. The company raised $59,596K in net proceeds from Series A preferred stock issuance and ended the period with $122,831K in cash. However, operating expenses surged to $15,882K (Q2) and $30,931K (six months) from near-zero levels a year ago, driven by R&D and G&A costs, while the accumulated deficit deepened to $95,907K.

• · Net loss per share (basic and diluted) was $(2.51) for Q2 2026 vs $(0.14) for Q2 2025; $(4.61) for six months 2026 vs $(0.34) for six months 2025.
• · Weighted-average shares outstanding (basic and diluted) increased to 7,401,783 (Q2 2026) from 2,792,409 (Q2 2025); 7,133,871 (six months 2026) from 1,403,918 (six months 2025).
• · Total liabilities increased to $9,342K at June 30, 2026 from $5,333K at December 31, 2025.
• · Operating lease right-of-use assets of $607K and lease liabilities of $575K were recognized in 2026 (none in prior period).
• · Stock-based compensation was $2,846K for six months 2026 (none in prior period).
• · Cash used in operating activities was $22,136K for six months 2026 vs $0 in prior period.
• · Cash used in investing activities was $3,028K (including $3,000K for in-process R&D) vs $0 in prior period.
• · Deferred offering costs of $2,811K were capitalized as of June 30, 2026 (none at December 31, 2025).
• · Accrued expenses and other current liabilities increased to $6,012K from $4,184K, driven by accrued R&D, compensation, clinical, and professional services.
• · Series A preferred stock shares increased by 60,000,000 during Q2 2026, with net proceeds of $59,596K.
• · Non-cash deemed dividends of $3,615K were recorded on issuance of Series A preferred stock.